Collegium Pharmaceutical, Inc. Deferred Income Tax Expense (Benefit)
Collegium Pharmaceutical, Inc. (COLL) reported Deferred Income Tax Expense (Benefit) of -$8.12 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for the quarter ending 2026-06-30 was -$7.16M.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for the quarter ending 2026-03-31 was -$968.00K.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for the quarter ending 2025-12-31 was -$10.07M.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for the quarter ending 2025-09-30 was -$12.13M.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for fiscal 2025 was -$25.66M.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for fiscal 2024 was -$26.81M.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for fiscal 2023 was -$2.15M.
- Collegium Pharmaceutical, Inc. deferred income tax expense (benefit) for fiscal 2022 was -$8.39M.
| Period end | Deferred Income Tax Expense (Benefit) 3 month | Deferred Income Tax Expense (Benefit) 6 month | Deferred Income Tax Expense (Benefit) 9 month | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.16M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$8.12M 10-Q · filed 2026-08-06 | -$18.20M derived: sum of 3 quarters · filed 2026-08-06 | -$30.33M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$968.00K 10-Q · filed 2026-05-07 | -$11.04M derived: sum of 2 quarters · filed 2026-05-07 | -$23.17M derived: sum of 3 quarters · filed 2026-05-07 | -$26.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$10.07M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$22.20M derived: sum of 2 quarters · filed 2026-02-26 | -$25.12M derived: sum of 3 quarters · filed 2026-08-06 | -$25.66M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$12.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$15.05M derived: sum of 2 quarters · filed 2026-08-06 | -$15.59M 10-Q · filed 2025-11-06 | -$25.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.91M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$3.45M 10-Q · filed 2026-08-06 | -$13.61M derived: sum of 3 quarters · filed 2026-08-06 | -$22.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$539.00K 10-Q · filed 2026-05-07 | -$10.70M derived: sum of 2 quarters · filed 2026-05-07 | -$19.43M derived: sum of 3 quarters · filed 2026-05-07 | -$22.94M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$10.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$18.89M derived: sum of 2 quarters · filed 2026-02-26 | -$22.40M derived: sum of 3 quarters · filed 2026-02-26 | -$26.81M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$8.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$12.25M derived: sum of 2 quarters · filed 2025-11-06 | -$16.66M 10-Q · filed 2025-11-06 | -$17.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$7.92M 10-Q · filed 2025-08-07 | -$8.26M derived: sum of 3 quarters · filed 2026-02-26 | -$9.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$4.41M 10-Q · filed 2025-05-08 | -$4.75M derived: sum of 2 quarters · filed 2026-02-26 | -$5.88M derived: sum of 3 quarters · filed 2026-02-26 | -$6.52M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.47M derived: sum of 2 quarters · filed 2026-02-26 | -$2.11M derived: sum of 3 quarters · filed 2026-02-26 | -$2.15M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$1.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.77M derived: sum of 2 quarters · filed 2024-11-07 | -$1.81M 10-Q · filed 2024-11-07 | -$2.89M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$682.00K 10-Q · filed 2024-08-08 | -$1.76M derived: sum of 3 quarters · filed 2025-02-27 | $337.00K derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$46.00K 10-Q · filed 2024-05-09 | -$1.12M derived: sum of 2 quarters · filed 2025-02-27 | $973.00K derived: sum of 3 quarters · filed 2025-02-27 | -$2.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.08M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $1.02M derived: sum of 2 quarters · filed 2025-02-27 | -$2.35M derived: sum of 3 quarters · filed 2025-02-27 | -$8.39M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$1.27M derived: sum of 2 quarters · filed 2023-11-07 | -$7.31M 10-Q · filed 2023-11-07 | -$22.33M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$3.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$9.41M 10-Q · filed 2023-08-03 | -$24.43M derived: sum of 3 quarters · filed 2024-02-22 | -$24.80M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$6.04M 10-Q · filed 2023-05-04 | -$21.05M derived: sum of 2 quarters · filed 2024-02-22 | -$21.43M derived: sum of 3 quarters · filed 2024-02-22 | -$84.08M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$15.39M derived: sum of 2 quarters · filed 2024-02-22 | -$78.04M derived: sum of 3 quarters · filed 2024-02-22 | -$78.04M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$377.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$63.03M derived: sum of 2 quarters · filed 2022-11-03 | -$63.03M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$62.65M 10-Q · filed 2021-08-05 | -$62.65M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 | ||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-06 | |||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-05 | $0.00 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |